338 related articles for article (PubMed ID: 22437759)
1. Role of transglutaminase 2 in celiac disease pathogenesis.
Klöck C; Diraimondo TR; Khosla C
Semin Immunopathol; 2012 Jul; 34(4):513-22. PubMed ID: 22437759
[TBL] [Abstract][Full Text] [Related]
2. Transglutaminase as a therapeutic target for celiac disease.
Sulic AM; Kurppa K; Rauhavirta T; Kaukinen K; Lindfors K
Expert Opin Ther Targets; 2015 Mar; 19(3):335-48. PubMed ID: 25410283
[TBL] [Abstract][Full Text] [Related]
3. Activation and inhibition of transglutaminase 2 in mice.
Dafik L; Albertelli M; Stamnaes J; Sollid LM; Khosla C
PLoS One; 2012; 7(2):e30642. PubMed ID: 22319575
[TBL] [Abstract][Full Text] [Related]
4. Are transglutaminase 2 inhibitors able to reduce gliadin-induced toxicity related to celiac disease? A proof-of-concept study.
Rauhavirta T; Oittinen M; Kivistö R; Männistö PT; Garcia-Horsman JA; Wang Z; Griffin M; Mäki M; Kaukinen K; Lindfors K
J Clin Immunol; 2013 Jan; 33(1):134-42. PubMed ID: 22878839
[TBL] [Abstract][Full Text] [Related]
5. Transglutaminase 2 inhibitors and their therapeutic role in disease states.
Siegel M; Khosla C
Pharmacol Ther; 2007 Aug; 115(2):232-45. PubMed ID: 17582505
[TBL] [Abstract][Full Text] [Related]
6. New therapeutic strategies for coeliac disease: tissue transglutaminase as a target.
Esposito C; Caputo I; Troncone R
Curr Med Chem; 2007; 14(24):2572-80. PubMed ID: 17979710
[TBL] [Abstract][Full Text] [Related]
7. Gliadin T cell epitope selection by tissue transglutaminase in celiac disease. Role of enzyme specificity and pH influence on the transamidation versus deamidation process.
Fleckenstein B; Molberg Ø; Qiao SW; Schmid DG; von der Mülbe F; Elgstøen K; Jung G; Sollid LM
J Biol Chem; 2002 Sep; 277(37):34109-16. PubMed ID: 12093810
[TBL] [Abstract][Full Text] [Related]
8. Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease.
Büchold C; Hils M; Gerlach U; Weber J; Pelzer C; Heil A; Aeschlimann D; Pasternack R
Cells; 2022 May; 11(10):. PubMed ID: 35626704
[TBL] [Abstract][Full Text] [Related]
9. Constitutive Differential Features of Type 2 Transglutaminase in Cells Derived from Celiac Patients and from Healthy Subjects.
Paolella G; Nanayakkara M; Sposito S; Lepretti M; Auricchio S; Esposito C; Barone MV; Martucciello S; Caputo I
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32059410
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and evaluation of gluten peptide analogs as selective inhibitors of human tissue transglutaminase.
Hausch F; Halttunen T; Mäki M; Khosla C
Chem Biol; 2003 Mar; 10(3):225-31. PubMed ID: 12670536
[TBL] [Abstract][Full Text] [Related]
11. Transglutaminase 2-targeted autoantibodies in celiac disease: Pathogenetic players in addition to diagnostic tools?
Lindfors K; Mäki M; Kaukinen K
Autoimmun Rev; 2010 Sep; 9(11):744-9. PubMed ID: 20547248
[TBL] [Abstract][Full Text] [Related]
12. Transglutaminase 2 undergoes a large conformational change upon activation.
Pinkas DM; Strop P; Brunger AT; Khosla C
PLoS Biol; 2007 Dec; 5(12):e327. PubMed ID: 18092889
[TBL] [Abstract][Full Text] [Related]
13. Tissue transglutaminase-mediated formation and cleavage of histamine-gliadin complexes: biological effects and implications for celiac disease.
Qiao SW; Piper J; Haraldsen G; Oynebråten I; Fleckenstein B; Molberg O; Khosla C; Sollid LM
J Immunol; 2005 Feb; 174(3):1657-63. PubMed ID: 15661929
[TBL] [Abstract][Full Text] [Related]
14. Enhanced B-Cell Receptor Recognition of the Autoantigen Transglutaminase 2 by Efficient Catalytic Self-Multimerization.
Stamnaes J; Iversen R; du Pré MF; Chen X; Sollid LM
PLoS One; 2015; 10(8):e0134922. PubMed ID: 26244572
[TBL] [Abstract][Full Text] [Related]
15. Recent Progress in the Development of Transglutaminase 2 (TGase2) Inhibitors.
Song M; Hwang H; Im CY; Kim SY
J Med Chem; 2017 Jan; 60(2):554-567. PubMed ID: 28122456
[TBL] [Abstract][Full Text] [Related]
16. Interferon-γ activates transglutaminase 2 via a phosphatidylinositol-3-kinase-dependent pathway: implications for celiac sprue therapy.
Diraimondo TR; Klöck C; Khosla C
J Pharmacol Exp Ther; 2012 Apr; 341(1):104-14. PubMed ID: 22228808
[TBL] [Abstract][Full Text] [Related]
17. The preferred substrates for transglutaminase 2 in a complex wheat gluten digest are Peptide fragments harboring celiac disease T-cell epitopes.
Dørum S; Arntzen MØ; Qiao SW; Holm A; Koehler CJ; Thiede B; Sollid LM; Fleckenstein B
PLoS One; 2010 Nov; 5(11):e14056. PubMed ID: 21124911
[TBL] [Abstract][Full Text] [Related]
18. Transglutaminase 2 in celiac disease: minireview article.
Caputo I; D'Amato A; Troncone R; Auricchio S; Esposito C
Amino Acids; 2004 Jul; 26(4):381-6. PubMed ID: 15290344
[TBL] [Abstract][Full Text] [Related]
19. Involvement of cell surface TG2 in the aggregation of K562 cells triggered by gluten.
Feriotto G; Calza R; Bergamini CM; Griffin M; Wang Z; Beninati S; Ferretti V; Marzola E; Guerrini R; Pagnoni A; Cavazzini A; Casciano F; Mischiati C
Amino Acids; 2017 Mar; 49(3):551-565. PubMed ID: 27699491
[TBL] [Abstract][Full Text] [Related]
20. Towards Celiac-safe foods: Decreasing the affinity of transglutaminase 2 for gliadin by addition of ascorbyl palmitate and ZnCl
Engstrom N; Saenz-Méndez P; Scheers J; Scheers N
Sci Rep; 2017 Mar; 7(1):77. PubMed ID: 28250436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
